Core Viewpoint - The company, Hualv Biotechnology, has reported significant growth in its product offerings and revenue, projecting a revenue of 1.032 billion yuan in 2024, which represents a substantial increase from 578 million yuan in 2021, indicating a doubling of both production capacity and revenue [1]. Group 1: Product Diversification - The main products of the company include enoki mushrooms, king oyster mushrooms (including crab-flavored and white jade varieties), maitake mushrooms, cordyceps flowers, and deer antler mushrooms, with the latter two being introduced after the company's IPO [1]. - The company has achieved industrialized production of edible mushroom products under its diversified layout, with ongoing inquiries about new specialty varieties [3]. Group 2: Capacity and Revenue Growth - The company anticipates that its revenue for 2024 will reach 1.032 billion yuan, which is a notable increase from 578 million yuan in 2021, reflecting a clear growth trajectory [1]. - The company has successfully doubled its production capacity and revenue since its listing, with specific inquiries regarding the new and expanded production bases planned for 2024 and 2025 [3].
华绿生物：目前主要产品有金针菇、真姬菇、虫草花，鹿茸菇等品类，其中虫草花、鹿茸菇为上市后推出的品种